TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34658247

Group type: EXPERIMENTAL
Intervention: Rivaroxaban monotherapy
Number of subjects: 2215

Group type: COMPARATOR
Intervention: Combination therapy with rivaroxaban plus antiplatelet drug
Number of subjects: 2215
Study: 36484671

Group type: EXPERIMENTAL
Intervention: Single-implant mandibular overdenture (SIMO)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional mandibular denture (CMD)
Number of subjects: 32
Study: 33706185

Group type: EXPERIMENTAL
Intervention: Sunscreen products (4 commercially available types)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LC-MS/MS method for avobenzone and oxybenzone
Number of subjects: 0
Study: 32235852

Group type: EXPERIMENTAL
Intervention: Kinesiologist-guided functional training in addition to intradialytic cycling
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intradialytic cycling only
Number of subjects: 40
Study: 33368797

Group type: EXPERIMENTAL
Intervention: Gilteritinib plus Azacitidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 32556409

Group type: EXPERIMENTAL
Intervention: Autologous graft for EAS repair
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biological graft for EAS repair
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mesh graft for EAS repair
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overly tight repair
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overly loose sphincter repair
Number of subjects: 0
Study: 35811663

Group type: EXPERIMENTAL
Intervention: Fast rehabilitation program
Number of subjects: 65

Group type: COMPARATOR
Intervention: Traditional rehabilitation program
Number of subjects: 65
Study: 33981386

Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen plus 0.1 mg/kg ondansetron intravenously
Number of subjects: 53

Group type: COMPARATOR
Intervention: Intravenous acetaminophen plus 2 ml of normal saline intravenously
Number of subjects: 53
Study: 32315287

Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV, MVA-BN-Filo vaccination regimen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ebola glycoprotein stimulation
Number of subjects: 0
Study: 35559648

Group type: EXPERIMENTAL
Intervention: Mobile health intervention with smartwatch and usual care
Number of subjects: 220
Study: 33221515

Group type: EXPERIMENTAL
Intervention: Aqueous chlorhexidine (AqCHX) 0.1%
Number of subjects: 50

Group type: COMPARATOR
Intervention: Povidone-Iodine (PI) 5%
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 32671667

Group type: EXPERIMENTAL
Intervention: Renal replacement therapy (RRT)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Baseline GFR > 60 mL/min/1.73 m2
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Baseline GFR < 60 mL/min/1.73 m2
Number of subjects: 151
Study: 35108739

Group type: EXPERIMENTAL
Intervention: UpToDate
Number of subjects: 26

Group type: COMPARATOR
Intervention: DynaMed Plus
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both resources
Number of subjects: 26
Study: 33158765

Group type: EXPERIMENTAL
Intervention: Nivolumab with chemotherapy (≤ 4 cycles of platinum-based chemotherapy with pemetrexed + nivolumab for ≤ 12 cycles as maintenance)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Nivolumab with chemotherapy
Number of subjects: 92

Group type: COMPARATOR
Intervention: Chemotherapy (≤ 4 cycles of platinum-based chemotherapy with pemetrexed)
Number of subjects: 92
Study: 33479838

Group type: EXPERIMENTAL
Intervention: Double cow-hitch technique
Number of subjects: 12

Group type: COMPARATOR
Intervention: Double tight-rope technique
Number of subjects: 12
Study: 34068730

Group type: EXPERIMENTAL
Intervention: Cooling recovery (cooling suit worn on lower legs)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no cooling suit)
Number of subjects: 12
Study: 32940628

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel, 260 mg/m2 every 3 weeks
Number of subjects: 199

Group type: COMPARATOR
Intervention: paclitaxel, 175 mg/m2 every 3 weeks
Number of subjects: 199
Study: 34903431

Group type: EXPERIMENTAL
Intervention: Pelvic radiotherapy with concurrent chemoradiotherapy followed by adjuvant chemotherapy
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Quality assurance in radiotherapy (QART) assessment
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Dosimetric evaluation using the TROG protocol
Number of subjects: 146
Study: 36266668

Group type: EXPERIMENTAL
Intervention: Continuous feeding
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Cyclic feeding
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intermittent feeding
Number of subjects: 90
Study: 35079588

Group type: EXPERIMENTAL
Intervention: Education via the Line application and telephone-based counseling (experimental group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard routine health education activities (control group)
Number of subjects: 60
Study: 36114871

Group type: EXPERIMENTAL
Intervention: Lumbar facet joint osteoarthritis (LFJOA) subgroup
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: LFJOA subgroup
Number of subjects: 18

Group type: COMPARATOR
Intervention: Non-LFJOA subgroup
Number of subjects: 18
Study: 34465828

Group type: EXPERIMENTAL
Intervention: ICH with advanced WMH
Number of subjects: 1454

Group type: COMPARATOR
Intervention: ICH with mild WMH
Number of subjects: 1454

Group type: EXPERIMENTAL
Intervention: Advanced WMH
Number of subjects: 1454

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 1454
Study: 36243785

Group type: EXPERIMENTAL
Intervention: 150-min of moderate-intensity exercise
Number of subjects: 192

Group type: COMPARATOR
Intervention: Non-exercising control
Number of subjects: 192
Study: 32944748

Group type: EXPERIMENTAL
Intervention: PFOA (perfluorooctanoic acid) serum concentration
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: PFOA (highest quartile vs lowest quartile)
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: PFOA (after adjustment for other PFAS)
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: PFOA (restricted to individuals without diminished kidney function)
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: PFOA (cases diagnosed 8 or more years after phlebotomy)
Number of subjects: 648
Study: 34310796

Group type: EXPERIMENTAL
Intervention: Care Transitions Intervention (CTI)
Number of subjects: 1756
Study: 34967362

Group type: EXPERIMENTAL
Intervention: Thick-layer technique (Exeter V40 Cemented Femoral Stem)
Number of subjects: 0

Group type: COMPARATOR
Intervention: French paradox technique (Müller Straight Stem)
Number of subjects: 0
Study: 35276486

Group type: EXPERIMENTAL
Intervention: Melatonin 36 mg (Mel 36 group; n=6)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Melatonin 18 mg (Mel 18 group; n=6)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (n=6)
Number of subjects: 18
Study: 33246338

Group type: EXPERIMENTAL
Intervention: 25-hydroxyvitamin D deficiency
Number of subjects: 1394

Group type: EXPERIMENTAL
Intervention: Homocysteine levels
Number of subjects: 1394

Group type: EXPERIMENTAL
Intervention: C-reactive protein (3-10 mg/L)
Number of subjects: 1394

Group type: EXPERIMENTAL
Intervention: Gray matter volume
Number of subjects: 1394

Group type: EXPERIMENTAL
Intervention: Hippocampal volume
Number of subjects: 1394

Group type: EXPERIMENTAL
Intervention: Omega-3 index
Number of subjects: 1394
Study: 36121865

Group type: EXPERIMENTAL
Intervention: CSB-MNP-A (multiple micronutrients containing zinc)
Number of subjects: 346

Group type: COMPARATOR
Intervention: Control (standard CSB fortified with multiple micronutrients)
Number of subjects: 346
Study: 34100498

Group type: EXPERIMENTAL
Intervention: Intact salmon
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Minced salmon
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Defatted salmon + oil
Number of subjects: 13

Group type: COMPARATOR
Intervention: Homogeneous unstructured meal
Number of subjects: 13
Study: 32856410

Group type: EXPERIMENTAL
Intervention: Vein viewing device
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no vein viewing device)
Number of subjects: 0
Study: 35748397

Group type: EXPERIMENTAL
Intervention: Lasmiditan 50 mg
Number of subjects: 691

Group type: EXPERIMENTAL
Intervention: Lasmiditan 100 mg
Number of subjects: 691

Group type: EXPERIMENTAL
Intervention: Lasmiditan 200 mg
Number of subjects: 691

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 691
Study: 33295007

Group type: EXPERIMENTAL
Intervention: Apalutamide + androgen deprivation therapy
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo + androgen deprivation therapy
Number of subjects: 51
Study: 35278643

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (ZnG) for 8 weeks
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo (PbG)
Number of subjects: 51
Study: 33692177

Group type: EXPERIMENTAL
Intervention: Trial protocol changes and training by the FEVER team
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Trial acceptability as perceived by parents and staff
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Concerns regarding temperature thresholds and pain management
Number of subjects: 81
Study: 32825070

Group type: EXPERIMENTAL
Intervention: Financial rewards
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Smart gamification
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of smart gamification and financial rewards
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no specific motivation)
Number of subjects: 0
Study: 35484828

Group type: EXPERIMENTAL
Intervention: Precision intraoperative nerve block with 0.3% ropivacaine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Traditional analgesia (superficial cervical plexus nerve block)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (saline injection)
Number of subjects: 120
Study: 33939289

Group type: EXPERIMENTAL
Intervention: Prophylactic soft silicone multi-layered foam dressings with loading
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Prophylactic soft silicone multi-layered foam dressings without loading
Number of subjects: 8

Group type: COMPARATOR
Intervention: No dressings with loading
Number of subjects: 8

Group type: COMPARATOR
Intervention: No dressings without loading
Number of subjects: 8
Study: 33061332

Group type: EXPERIMENTAL
Intervention: Intensified postoperative physical therapy treatment including daily supervised early mobilization and coached deep breathing exercises with positive expiratory pressure (PEP)
Number of subjects: 69
Study: 34997449

Group type: EXPERIMENTAL
Intervention: FTD/TPI 35 mg/m2
Number of subjects: 507

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 507
Study: 33762689

Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum subsp. infantis (B. infantis) EVC001 (EVC) daily for 21 days
Number of subjects: 48

Group type: COMPARATOR
Intervention: Breast milk alone (unsupplemented (UNS))
Number of subjects: 48
Study: 35321558

Group type: EXPERIMENTAL
Intervention: Non-RAS inhibitors (calcium channel blockers and diuretics)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: RAS inhibitors (ACE inhibitors, ARBs, and β-blockers)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Baseline RAS inhibitor or non-inhibitor treatments
Number of subjects: 203
Study: 34460179

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 0
Study: 32968290

Group type: EXPERIMENTAL
Intervention: Self-medication practices
Number of subjects: 426
Study: 35020795

Group type: EXPERIMENTAL
Intervention: FA-modified dairy diet
Number of subjects: 52

Group type: COMPARATOR
Intervention: Conventional dairy diet
Number of subjects: 52
Study: 33471104

Group type: EXPERIMENTAL
Intervention: Exercise intervention (EIM) plus usual care
Number of subjects: 198

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 198
Study: 35815801

Group type: EXPERIMENTAL
Intervention: Brigatinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alectinib
Number of subjects: 0
Study: 33545940

Group type: EXPERIMENTAL
Intervention: Healing Touch (HT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 34907064

Group type: EXPERIMENTAL
Intervention: Physiotherapy and cognitive behavioural therapy (CBT) for 9 weeks each
Number of subjects: 60

Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 60
Study: 33566093

Group type: EXPERIMENTAL
Intervention: Problem-oriented view (POV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard view (SV)
Number of subjects: 0
Study: 32912514

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 3876

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3876
Study: 35817742

Group type: EXPERIMENTAL
Intervention: Predictive nomogram for survival in ICU patients receiving mechanical ventilation
Number of subjects: 16775
Study: 34657055

Group type: EXPERIMENTAL
Intervention: Regorafenib (Rego) 160 mg/kg body weight orally every 28 days for 21 days
Number of subjects: 8

Group type: COMPARATOR
Intervention: S-1 plus Bevacizumab (SB), S-1 orally every 42 days for 28 days and Bev 5 mg/kg intravenously on days 1, 15, and 29
Number of subjects: 8
Study: 33369354

Group type: EXPERIMENTAL
Intervention: Focused ultrasound subthalamotomy (active treatment)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham procedure (control)
Number of subjects: 40
Study: 32691610

Group type: EXPERIMENTAL
Intervention: Behavioural assessment tools (specifically the Dementia Observation System (DOS) and Cohen-Mansfield Agitation Inventory (CMAI))
Number of subjects: 103
Study: 32389574

Group type: EXPERIMENTAL
Intervention: JR-051
Number of subjects: 0
Study: 34924287

Group type: EXPERIMENTAL
Intervention: GnRHa supplementation (two boluses of triptorelin 0.1 mg)
Number of subjects: 287

Group type: COMPARATOR
Intervention: Control group (standard HRT-FET protocol only)
Number of subjects: 287
Study: 32598098

Group type: EXPERIMENTAL
Intervention: 10% sodium ascorbate
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: 10% grape seed extract
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: 10% green tea extract
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: 5% alpha‐lipoic acid
Number of subjects: 110

Group type: COMPARATOR
Intervention: No antioxidant (positive control)
Number of subjects: 110

Group type: COMPARATOR
Intervention: 40% hydrogen peroxide (bleaching agent)
Number of subjects: 110

Group type: COMPARATOR
Intervention: 35% carbamide peroxide (bleaching agent)
Number of subjects: 110

Group type: COMPARATOR
Intervention: No bleaching-no antioxidant (negative control, group A)
Number of subjects: 110
Study: 32210461

Group type: EXPERIMENTAL
Intervention: Insect-based feed (IBF)
Number of subjects: 957
Study: 35315627

Group type: EXPERIMENTAL
Intervention: Perioperative cognitive therapy combined with rehabilitation exercise
Number of subjects: 86

Group type: COMPARATOR
Intervention: Standardized health care service (control group)
Number of subjects: 86
Study: 34201981

Group type: EXPERIMENTAL
Intervention: Custom-made foot orthotics (n = 53)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Non-biomechanical effect orthoses (Control group, n = 48)
Number of subjects: 101
Study: 34321436

Group type: EXPERIMENTAL
Intervention: RENEwS (emotion regulation intervention)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Attention control (phone-based)
Number of subjects: 30
Study: 33793078

Group type: EXPERIMENTAL
Intervention: Oat consumption (80 g oats containing 3 g beta-glucan daily for 45 days)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Rice consumption (control group)
Number of subjects: 62
Study: 36251392

Group type: EXPERIMENTAL
Intervention: Direct bonding (DB) with two-step adhesive
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Direct bonding (DB) with one-step adhesive
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Indirect bonding (IDB) with two-step adhesive
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Indirect bonding (IDB) with one-step adhesive
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 100
Study: 34801006

Group type: EXPERIMENTAL
Intervention: App-based intervention including unintentional injury prevention
Number of subjects: 3508

Group type: COMPARATOR
Intervention: Routine school-based education plus app-based parenting education excluding unintentional injury prevention
Number of subjects: 3508
Study: 34815362

Group type: EXPERIMENTAL
Intervention: Annual chlamydia testing through general practice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Doubling the retesting rate within 4 months of treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increasing partner treatment rate from 30% to 50%
Number of subjects: 0
Study: 32272288

Group type: EXPERIMENTAL
Intervention: saMS CBT
Number of subjects: 94

Group type: COMPARATOR
Intervention: SL
Number of subjects: 94
Study: 36180944

Group type: EXPERIMENTAL
Intervention: Liver transplantation (LT) + best established treatment (BET)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best established treatment only (BET)
Number of subjects: 0
Study: 34588268

Group type: EXPERIMENTAL
Intervention: Amniocentesis-based predictor models
Number of subjects: 340

Group type: COMPARATOR
Intervention: Standard institutional protocols (Control)
Number of subjects: 340
Study: 32752904

Group type: EXPERIMENTAL
Intervention: GLA‐SE‐Schedule 1
Number of subjects: 23

Group type: COMPARATOR
Intervention: SE‐Schedule 2
Number of subjects: 23
Study: 34838115

Group type: EXPERIMENTAL
Intervention: Enhanced screening program for early detection of lung, liver, anal, cervical, breast, prostate, colorectal, and skin cancer.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care screening according to European AIDS Clinical Society recommendations.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enhanced screening program for early detection of cancer.
Number of subjects: 0
Study: 33761679

Group type: EXPERIMENTAL
Intervention: Tanreqing injection combined with azithromycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Azithromycin
Number of subjects: 0
Study: 33415857

Group type: EXPERIMENTAL
Intervention: Liyan Tongqiao acupuncture
Number of subjects: 60

Group type: COMPARATOR
Intervention: Neurology treatment
Number of subjects: 60
Study: 35617104

Group type: EXPERIMENTAL
Intervention: Treosulfan (30 g/m2 IV)
Number of subjects: 570

Group type: COMPARATOR
Intervention: Busulfan (6.4 mg/kg IV)
Number of subjects: 570
Study: 34145306

Group type: EXPERIMENTAL
Intervention: Uridine + pyruvate supplementation (Uripyr)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (mitotoxic antibiotic without supplementation)
Number of subjects: 55
Study: 32195962

Group type: EXPERIMENTAL
Intervention: Tablet computer-based cognitive training program (30 minutes per session, twice a week for 12 weeks)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Tablet computer-based cognitive training program
Number of subjects: 38

Group type: COMPARATOR
Intervention: Traditional rehabilitation program (control)
Number of subjects: 38
Study: 35462581

Group type: EXPERIMENTAL
Intervention: Double faced transverse preputial onlay island flap (group A)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Transverse inner preputial flap (control group, group B)
Number of subjects: 68
Study: 34107730

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Sham procedure (control)
Number of subjects: 49
Study: 32539832

Group type: EXPERIMENTAL
Intervention: Anagliptin
Number of subjects: 307

Group type: COMPARATOR
Intervention: Sitagliptin
Number of subjects: 307
Study: 35767175

Group type: EXPERIMENTAL
Intervention: CoolSense
Number of subjects: 140

Group type: COMPARATOR
Intervention: EMLA cream
Number of subjects: 140
Study: 33909260

Group type: EXPERIMENTAL
Intervention: Shuanghuanglian (SHL) treatment (14-day treatment)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: High-dose Shuanghuanglian (SHL) treatment
Number of subjects: 176

Group type: COMPARATOR
Intervention: Standard therapy alone
Number of subjects: 176
Study: 35687528

Group type: EXPERIMENTAL
Intervention: delamanid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: bedaquiline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: delamanid+bedaquiline
Number of subjects: 0
Study: 34393131

Group type: EXPERIMENTAL
Intervention: 25% propolis
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Calcium Hydroxide (Ca(OH)2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 25% Glycyrrhiza glabra
Number of subjects: 60
Study: 33011482

Group type: EXPERIMENTAL
Intervention: Group B (hyperglycemia + normal WBC)
Number of subjects: 4181

Group type: EXPERIMENTAL
Intervention: Group C (normal glucose + high WBC)
Number of subjects: 4181

Group type: EXPERIMENTAL
Intervention: Group D (hyperglycemia + high WBC)
Number of subjects: 4181

Group type: COMPARATOR
Intervention: Group A (normal glucose + normal WBC)
Number of subjects: 4181
Study: 35524205

Group type: EXPERIMENTAL
Intervention: Camrelizumab plus chemotherapy (IO-CT)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Camrelizumab plus chemoradiation (IO-CRT)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Chemoradiation (CRT)
Number of subjects: 204
Study: 33219852

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study: 34649284

Group type: EXPERIMENTAL
Intervention: E2 (exogenous estrogen)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study: 34537440

Group type: EXPERIMENTAL
Intervention: Brigatinib 180 mg once daily (7-day lead-in at 90 mg once daily)
Number of subjects: 275

Group type: COMPARATOR
Intervention: Crizotinib 250 mg twice daily
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Brigatinib
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Brigatinib in patients with baseline brain metastases
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Brigatinib and Crizotinib
Number of subjects: 275
Study: 35591811

Group type: EXPERIMENTAL
Intervention: Traditional moderate-intensity exercise (TRAD)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Stair climbing-based high-intensity interval exercise (STAIR)
Number of subjects: 18
Study: 33766695

Group type: EXPERIMENTAL
Intervention: Structured hypertension education program (once weekly education session for 4 weeks, home blood pressure monitoring, dose changes in antihypertensives)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group (routine care)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Structured hypertension education program
Number of subjects: 132